Combination therapy with alendronate and alphacalcidol for prevention of symptomatic vertebral fracture in elderly patients treated with high-dose glucocorticoid: a multicenter open-label randomized controlled trial. - ALIS study

Society for glucocorticoid-induced osteoporosis0 sites200 target enrollmentOctober 1, 2010

Overview

No summary available.

Registry

who.int

Start Date

October 1, 2010

End Date

March 1, 2014

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Society for glucocorticoid-induced osteoporosis

•1\)Patient who was not treated for more than 6 months (except, who had symptomatic vertebral fractures). 2\)Patient who has serious renal disorder (EGFR: \<35ml or Cre: more than 1\.5mg/ml). 3\)Patient who has a history of renal stone past 5 years. 4\)Patient with primary or secondary hyperparathyroidism. 5\)Patient with hyperthyroidism or hypothyroidism. 6\)Patients who is diagnosed as contraindication of alendronate treatements or Alfacalcidol. 7\)Patient who are treated with warfarin. 8\)Patient who is inappropriate for this study by physician. 9\)Patient who has experiences of receiving bisphosphonate treatment within 6 months at inclusion of the study. 10\)Patient who has experiences of receiving drugs having influence on bone remodeling within 6 months at inclusion of the study (Estrogen, Vitamin D, Calcitonin, Raloxifene, Ipriflavone, Vitamin K, Steroid)